Effects of permanent dual chamber pacing on myocardial perfusion in symptomatic hypertrophic cardiomyopathy

J L Posma, P K Blanksma, E E Van Der Wall, W Vaalburg, H J G M Crijns, K I Lie

Abstract

Objective—Angina and the presence of myocardial ischaemia are common in hypertrophic cardiomyopathy. Dual chamber pacing results in clinical improvement in these patients. This study evaluates the effects of permanent dual chamber pacing on absolute regional myocardial perfusion and perfusion reserve.

Setting—University hospital.

Patients and design—Six patients with hypertrophic cardiomyopathy and severe symptoms of angina received a dual chamber pacemaker. Absolute myocardial regional perfusion and perfusion reserve (dipyridamole 0·56 mg/kg) were measured by dynamic positron emission tomography with 15N-ammonia both during sinus rhythm and 3 months after pacemaker insertion. Results were compared with those from 28 healthy volunteers.

Results—Pacing resulted in a reduction of anginal complaints and a reduction in intraventricular pressure gradient from 65 (SD 30) mm Hg to 19 (10) mm Hg. During sinus rhythm, baseline perfusion was higher in patients with hypertrophic cardiomyopathy than controls (184 (31) vs 106 (26) ml/min/100 g, P < 0·01), and perfusion reserve was lower (1·6 (0·4) vs 2·8 (1·0), P < 0·05). During pacing myocardial perfusion decreased to 130 (27) ml/min/100 g (P < 0·05), with variable responses in terms of perfusion reserve. Pacing caused a redistribution of myocardial stress perfusion and perfusion reserve. The coefficient of regional variation of myocardial stress perfusion decreased from 19·7 (7·0)% to 14·6 (3·9)% during pacing (12·9 (3·8)% in controls, P < 0·01). The coefficient of regional variation of perfusion reserve decreased from 16·7 (6·6)% to 11·4 (2·6)% during pacing (9·8 (4·1)% in controls, P < 0·01).

Conclusions—Pacing caused a decrease of resting left ventricular myocardial blood flow and blood flow during pharmacologically induced coronary vasodilatation. Although global perfusion reserve remained unchanged, myocardial perfusion reserve became more homogeneously distributed.

Keywords: hypertrophic cardiomyopathy; pacing; perfusion imaging

Patients with hypertrophic cardiomyopathy typically complain of dyspnoea, angina, and presyncope and/or syncope on exertion. Considerable evidence points to the importance of myocardial ischaemia in patients with hypertrophic cardiomyopathy, especially in young patients in whom ischaemia is frequently related to sudden cardiac death. Myocardial ischaemia has been repeatedly demonstrated in both obstructive and non-obstructive hypertrophic cardiomyopathy by the presence of fixed and reversible thallium perfusion defects, by measurement of myocardial lactate production, particularly during rapid atrial pacing, and by positron emission tomography (PET).

Permanent dual chamber (DDD) pacing improves subjective symptoms in about 80% of the patients with drug refractory obstructive hypertrophic cardiomyopathy. Right ventricular pacing is believed to exert its beneficial haemodynamic effects by reducing the left ventricular outflow gradient by creating abnormal septal motion. The mechanisms by which pacing can improve symptoms in patients with the disease remain speculative but altered myocardial metabolism is a prime candidate. Exercise thallium-201 scintigraphy showed a decrease in perfusion defects during DDD pacing in several patients with hypertrophic cardiomyopathy but the effects of DDD pacing on absolute myocardial blood flow and flow reserve are unknown. Therefore, we studied myocardial perfusion in a group of six patients with hypertrophic cardiomyopathy by means of nitrogen-13 ammonia PET before and during permanent DDD pacing.

Patients and methods

PATIENTS

The baseline characteristics of the six patients are described in table 1. In each patient, the diagnosis of hypertrophic cardiomyopathy was based on cross sectional echocardiography, showing a hypertrophied, non-dilated left ventricle in the absence of identifiable cardiac or systemic stimuli to hypertrophy. All had severe symptoms of chest pain despite the use of adequate doses of calcium entry blockers and/or a β-blocking agent. The patients were symptomatic at rest or on minimal exercise. All patients had disproportionate thickening of
Effects of permanent dual chamber pacing on myocardial perfusion in symptomatic hypertrophic cardiomyopathy

Table 1 Baseline characteristics of the six study patients with hypertrophic cardiomyopathy

<table>
<thead>
<tr>
<th>Case/age/sex</th>
<th>NYHA FC</th>
<th>Symptoms</th>
<th>Prior medications</th>
<th>Septal/lateral wall thickness (mm)</th>
<th>LVOT gradient (mm Hg)</th>
<th>SR/pacing</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 55/M</td>
<td>IV</td>
<td>AP, FA</td>
<td>Verapamil</td>
<td>23/11</td>
<td>10/6</td>
<td>5R/6L</td>
</tr>
<tr>
<td>2 57/M</td>
<td>IV</td>
<td>AP, D</td>
<td>Verapamil, metoprolol, amiodarone</td>
<td>35/12</td>
<td>66/15</td>
<td></td>
</tr>
<tr>
<td>3 24/F</td>
<td>III</td>
<td>AP, D</td>
<td>Verapamil, disopyramide</td>
<td>22/10</td>
<td>8/8</td>
<td></td>
</tr>
<tr>
<td>4 37/F</td>
<td>IV</td>
<td>AP, D, FA</td>
<td>Verapamil, metoprolol</td>
<td>23/20</td>
<td>10/30</td>
<td></td>
</tr>
<tr>
<td>5 74/P</td>
<td>III</td>
<td>AP, D, S</td>
<td>Diltiazem</td>
<td>17/12</td>
<td>45/12</td>
<td></td>
</tr>
<tr>
<td>6 39/F</td>
<td>III</td>
<td>AP, S</td>
<td>Verapamil, amiodarone</td>
<td>22/11</td>
<td>77/17</td>
<td></td>
</tr>
</tbody>
</table>

AP, angina pectoris; D, dyspnea; F, female; FA, fatigue; FC, functional class; LVOT, left ventricular outflow tract; M, male; NYHA, New York Heart Association; S, syncope; SR, sinus rhythm.

Pacemaker Therapy

DDD permanent pacemakers were implanted in five patients and a VDD pacemaker in one patient by standard techniques (ventricular lead at right ventricular apex). Ventricular capture was maintained at maximum exercise by programming the resting atrioventricular delay to 90 (7) ms, and activating the rate-adaptive atrioventricular interval shortening. Three months after pacemaker insertion a repeat cross sectional echocardiogram with Doppler and PET study were performed in each patient. PET data were compared with the results obtained from 28 healthy volunteers.

PET Imaging Protocol

Myocardial perfusion was studied before and after pacemaker insertion with dynamic PET, according to the methods of Schelbert et al. and Bellina et al. using 13N-ammonia as tracer. All medication was stopped two days before the PET procedure. Subjects were positioned in an ECAT Siemens 951/31 positron camera, imaging 31 planes simultaneously over 10-8 cm. Photon attenuation was corrected using a retractable external ring source filled with 68Ge/68Ga. Dynamic imaging was started at the time of 13N-ammonia injection (370 MBq) and was continued for 15 min (frames: 12 x 10 s, 1 x 2 min, 1 x 4 min, 1 x 7 min). The resting study was followed by a stress study with dipyridamole, which was performed by injecting 0.56 mg dipyridamole/kg body weight over four minutes. 13N-ammonia was injected 2-3 min after the end of the dipyridamole administration.

PET Image Analysis

Data for each study were reoriented to short axis images using a manually drawn long axis in the left ventricle. The total myocardium was divided into nine regions, as described previously. For all regions time activity curves were assessed using maximum activity. In each region absolute myocardial perfusion at rest and during dipyridamole were assessed. Myocardial perfusion reserve was defined as the ratio of dipyridamole stimulated and resting perfusion. Corrections for partial volume effects, and thus for the underestimate of counts in normal walls, and for spillover from the left ventricular cavity and the surrounding tissue were based on echocardiographic measurements of regional wall thickness and wall motion in all nine segments. To compensate for the decrease in ammonia extraction with increase in flow rates a correction was applied as described earlier. Myocardial perfusion values were not corrected for the rate-pressure product because in patients with a dynamic left ventricular outflow tract obstruction the actual intraventricular pressure at the moment of imaging is not exactly known. Myocardial perfusion and perfusion reserve were calculated as a mean value of all nine regions, and separately as a mean value for four anterior and septal regions and for four posterior and lateral regions. As a measure of heterogeneity of myocardial perfusion and perfusion reserve, the coefficient of regional variation of perfusion and perfusion reserve of the nine regions was calculated (standard deviation/mean x 100), as described previously.

Statistical Analysis

All results are expressed as mean (SD). The significance of differences was tested using non-parametric statistical analysis (Wilcoxon signed rank test for paired data and Mann-Whitney U test for unpaired data). A P value < 0.05 was regarded as statistically significant.

Results

In all six patients a considerable reduction (from NYHA class III/IV to II) was seen in the severity of symptoms during DDD pacing. The intraventricular pressure gradients responded with a reduction from 65 (30) mm Hg to 19 (10) mm Hg. Rate-pressure product measured at the time of PET did not change significantly during pacing, and was not significantly different in controls and patients at baseline. Table 2 summarises baseline myocardial perfusion, myocardial perfusion during dipyridamole stress, and the perfusion reserve of the patients with hypertrophic cardiomyopathy and the 28 normal volunteers. It also shows the PET results three months after pacemaker implantation. In patients with hypertrophic cardiomyopathy, baseline myocardial perfusion was higher than in normal
volunteers (P < 0.01), but during dipyridamole stress myocardial perfusion was not statistically different from the corresponding values in the normal volunteers. This results in an impaired perfusion reserve in patients with hypertrophic cardiomyopathy (1-6 (0-4) v 2-8 (1-0) in controls, P < 0-05). During pacing a decrease in resting and stress myocardial perfusion was seen in all six patients when compared with baseline measurements (P < 0-05) together with an increase in perfusion reserve in four patients. Both during sinus rhythm and DDD pacing the posterolateral segments showed more myocardial perfusion during dipyridamole stress than the anteroseptal segments (P < 0-05), resulting in a higher perfusion reserve in the posterolateral wall. During sinus rhythm, stress perfusion and perfusion reserve were less evenly distributed in hypertrophic cardiomyopathy than in the controls; the coefficient of regional variation of stress perfusion was 19.7 (7.0)% v 12.9 (3.8)% (P < 0.01), and the coefficient of regional variation of perfusion reserve was 16.7 (6.6)% v 9.8 (4.1)% (P < 0.01). During DDD pacing the regional distribution of stress perfusion and perfusion reserve became almost normal in patients with hypertrophic cardiomyopathy; the coefficient of regional variation was 14.6 (3.9)% for stress perfusion, and 11.4 (2.6)% for perfusion reserve. The posterolateral/anteroseptal wall flow ratio during pharmacological stress decreased from 1.39 (0.25) to 1.19 (0.11) during DDD pacing.

**Discussion**

Speculation about the mechanism of benefit of DDD pacing in patients with hypertrophic cardiomyopathy has focused on left ventricular outflow tract obstruction and its reduction with pacing. Less attention has been paid to the effects of pacing on myocardial metabolism. Recent animal studies have demonstrated that pacing causes segmental differences in contractile work and induces a decrease of myocardial oxygen consumption in early activated regions. The pattern of ventricular activation during right ventricular pacing mimics that of left bundle branch block. This condition is known to be associated with a decrease in septal myocardial perfusion. So in patients with hypertrophic cardiomyopathy pacing might influence myocardial perfusion not only by a reduction in outflow gradient, and thus global oxygen demand, but also by direct effects of the altered activation pattern on local myocardial oxygen demand that are not specific to this disease.

We found that myocardial perfusion at baseline was higher than in normal controls. At variance with our findings, Camici et al. did not find differences in blood flow between 23 patients with hypertrophic cardiomyopathy and 12 control subjects using the same PET method as we did. However, in their study only nine of the 23 patients reported a history of typical chest pain, and only one of these patients showed systolic anterior motion of the mitral valve that is usually seen in patients with obstruction of the left ventricular outflow tract. In the nine patients with typical angina they did indeed find a higher baseline regional myocardial blood flow both in the septum and in the free wall. In our study group all patients had severe angina, and five had significant outflow tract obstruction. Using great cardiac vein flow measurements Cannon et al. showed that myocardial oxygen consumption and coronary blood flow were significantly higher in patients with obstructive lesions than in those without. So the differences in baseline clinical characteristics may explain the differences in baseline flow between our results and those of Camici et al. During sinus rhythm we found that coronary vasodilator reserve was lower in all six patients with hypertrophic cardiomyopathy than in the controls. This difference appears to be related to a higher baseline flow rather than to a reduction in maximal flow. The finding of impaired flow reserve in hypertrophic cardiomyopathy accords with the previously reported study of Camici et al. with the study of Koga et al. using split-dose thallium-dipyridamole scintigraphy, and with results on coronary flow dynamics and reserve assessed by transoesophageal echocardiography reported by Memmola et al. The exact cause of the decreased vasodilator capacity is not known and may be related to regional abnormalities or small vessel disease. Furthermore, impaired relaxation of the myocardium during the isovolumic and rapid filling periods could impair coronary filling. On the other hand, myocardial ischaemia might affect relaxation, causing a vicious cycle of diminished perfusion and impaired relaxation. In patients with
Effects of permanent dual chamber pacing on myocardial perfusion in symptomatic hypertrophic cardiomyopathy

Obstructive hypertrophic cardiomyopathy other possible explanations for impaired coronary flow delivery are a greater dependence of myocardial perfusion on diastole because of systolic vascular compression with prolonged systolic ejection time, and lower coronary perfusion pressure secondary to the subcoronary obstruction.28

The effects of different treatment strategies in patients with hypertrophic cardiomyopathy on myocardial perfusion have been investigated in only a few studies.19 20 Cannon et al4 using thallium-201 scintigraphy, assessed the impact of surgical relief of left ventricular outflow obstruction on myocardial perfusion abnormalities in 20 patients with symptomatic obstructive hypertrophic cardiomyopathy. In patients with the greatest reduction in rest outflow gradient they found partial or complete normalisation of myocardial perfusion abnormalities on the images six months after the operation. Fine et al21 described a patient in whom a thallium-201 SPECT scintigram became normal during verapamil treatment. By contrast, Gistri et al32 could not demonstrate a change in absolute myocardial blood flow and flow reserve after verapamil treatment with PET and "Na-ammonia in 20 patients. In one patient they found a redistribution of myocardial blood flow favouring the subendocardial regions after verapamil treatment.32 Two studies reported the effects of DDD pacing on thallium-201 scintigraphy in obstructive hypertrophic cardiomyopathy.2 17 Fananapazir et al examined 27 patients and found perfusion defects at exercise scintigraphy in 81% of the patients. After an eight weeks of DDD pacing, the perfusion abnormalities normalised or improved in 65%, but worsened in 17% of the patients.17 Recently, a patient was reported in whom dipyridamole and exercise thallium-201 image showed severe reversible defects in the septum, inferior wall, and apex.2 After a month of DDD pacing repeated thallium-201 scintigraphy showed almost completely normal images.2 These observations show that DDD pacing has a beneficial effect on ischaemia in patients with hypertrophic cardiomyopathy. However, compared with thallium-201 scintigraphy, PET imaging offers major advantages with its potential to quantitatively study regional myocardial perfusion because of its ability to correct for attenuation.35 In patients with a global decrease or increase in myocardial perfusion a thallium scintigram would be normal. By contrast, PET imaging can provide absolute flow measurements in every desired segment of the myocardium. A previous case report was published from our institution describing a patient with non-obstructive hypertrophic cardiomyopathy studied with PET before and after pacemaker implantation.34 In that patient we found a decrease in resting perfusion during pacing without a change in perfusion reserve. This was associated with a redistribution of perfusion reserve favouring the anteroseptal segments.

Compared with that patient with non-obstructive hypertrophic cardiomyopathy, the study group presently described showed less pronounced changes in the distribution of myocardial perfusion. With pacing, there was a non-significant trend towards a more homogeneous distribution, probably caused by the same mechanism as in non-obstructive hypertrophic cardiomyopathy27; anteroseptal fibre strain and thereby oxygen demand are reduced by early activation caused by right ventricular apical pacing.25 27 However, when pacing patients with hypertrophic cardiomyopathy another major factor may be operating. Pacing in this population causes a reduction in left ventricular outflow tract obstruction and left ventricular end diastolic pressure. This results in a lower myocardial oxygen demand combined with an increased diastolic transcoronary perfusion gradient. Our results support this mechanism; the lower resting perfusion during DDD pacing reflects a lower oxygen demand in all parts of the left ventricle caused by a lower systolic left ventricular pressure. During pacing mean myocardial perfusion reserve remained depressed when compared with controls, but the individual responses were very varied. Perfusion reserve increased in three patients, but actually decreased in another patient. This is in line with the variable results found by Fananapazir et al using thallium-201 scintigraphy.17 We found no relation between the individual effect of pacing on myocardial perfusion reserve and the clinical and haemodynamic responses to pacing or baseline clinical or morphological characteristics.

It is not known why not all patients with obstructive hypertrophic cardiomyopathy respond favourably to DDD pacing with an increase in perfusion reserve and why DDD pacing causes a reduction in hyperaemic myocardial perfusion. We have only short-term follow up on a few patients and do not know whether this possibly deleterious effect of pacing may be detrimental in the long term. Further research is necessary, especially in those patients in whom pacing induces a reduction in hypertrophy.35 In addition, it is unclear whether pacing results in ventricular dilatation and heart failure on the long run.35 At present, cautious optimism is warranted regarding pacemaker treatment in patients with obstructive hypertrophic cardiomyopathy.36 One has to wait until prospective studies are available and the effects of pacing on myocardial perfusion and other pathophysiological mechanisms are better understood.

5 Takata J, Coughlan P, Gane IN, Yoshinori D, Chikamori T, Ozawa T, et al. Regional thallium-201 washout and

---

Medical information is presented for educational purposes only, and is not intended to replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider regarding any questions you may have regarding a medical condition. Always consult your healthcare provider before making any changes to your treatment regimen or medication regimen.


